CAI/II-IN-12
CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma.
For research use only. We do not sell to patients.
- Formula: C26H24N4O5S
- Molecular Weight:504.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
hCA I 7.12 μM (IC50) |
hCA II 10.62 μM (IC50) |
CAI/II-IN-12 (Compound 6d) (1-100 μM, 24 h) shows selective inhibitory activity against prostate cancer cells (DU145) and low toxicity against normal cells (PNT1a)[1].
CAI/II-IN-12 demonstrates significant potential to establish a coordination bond between the carbonyl oxygen of its triazole moiety and the central iron atom within the HEM group of the enzyme upon binding to CYP17A1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145 cells, PNT1a cells
-
Concentration:1 μM, 10 μM, 100 μM
-
Incubation Time:24 h
-
Result:In DU145 cancer cells, exhibited dose-dependent inhibition of cell viability.
In normal PNT1a cells, the IC50 value was 113.44 μM, and the selectivity index (SI) was 2.28.
Chemical Information
-
Molecular Weight 504.56
-
Formula C26H24N4O5S
-
SMILES
O=S(C1=CC=C(C)C=C1)(OC2=CC=CC(/C=N/N3C(CC4=CC=C(C)C=C4)=NN(C(C)=O)C3=O)=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)